Search
Webinar
Thursday, 17 September 2026
11:30 am New Delhi | 2:00 pm Singapore | 3:00 pm Tokyo/Seoul | 4:00 pm Sydney
The rapid growth of RNA-based therapeutics and other complex biotherapeutic modalities is driving new analytical and regulatory challenges for LC–MS workflows. Impurity characterization is particularly demanding, as closely related impurities often coelute with the active molecule, while issues such as limited chromatographic resolution, metal adduct formation, and inconsistent MS data can compromise confidence in results.
In this webinar, we introduce a next-generation LC–MS strategy designed to address these gaps. By combining advanced reversed-phase chromatography with an inert UHPLC flow path, this approach improves separation of challenging species, minimizes metal adducts, and delivers more consistent, more interpretable MS data across diverse modalities.
Using the Thermo Scientific™ SurePac™ RP MDi™ column on the Thermo Scientific™ Vanquish™ Amplify UHPLC system coupled with Orbitrap™ MS, we will demonstrate how this approach enhances analytical performance in real-world applications, including impurity profiling for small single stranded oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs), using a DoE-driven approach.
Learning objectives:
- Understand how advanced LC–MS workflows enable comprehensive characterization of ASOs, including confirmation of primary structure, analysis of the 5′ and 3′ termini, site-specific modifications, and product-related impurities.
- Evaluate how inert column technologies and UHPLC systems improve analytical performance by enhancing reproducibility, reducing sample interactions, minimizing metal adducts, and increasing workflow robustness.
- Apply Design of Experiments (DoE)-driven LC–MS strategies for impurity profiling and comprehensive characterization of complex biotherapeutics.
Join us to see how this workflow can unlock deeper characterization and more confident results across today’s most demanding biotherapeutic modalities.
Who Should Attend?
This webinar is ideal for scientists and laboratory professionals involved in LC-MS method development, optimization, characterization, and troubleshooting for complex biotherapeutics, including RNA-based therapies and oligonucleotide therapeutics such as ASOs.
It will be especially valuable for:
- Analytical chemists and LC-MS specialists working in biotherapeutics
- Researchers focused on oligonucleotide characterization, impurity profiling, and comprehensive analysis
- Method development, validation, and troubleshooting scientists
- Teams looking to improve chromatographic separation, reduce metal adducts, and enhance MS data quality
- R&D and quality control professionals seeking more robust LC-MS workflows for challenging modalities
Whether you are developing new workflows or refining existing ones, this session will provide practical insights for improving reproducibility, separation performance, and overall analytical confidence.
Speakers
Silvia Millán-Martín, PhD
Senior Research Scientist
National Institute for Bioprocessing Research and Training (NIBRT)
Silvia is a Senior Research Scientist at the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland. She collaborates with Thermo Fisher Scientific to develop innovative applications for the characterization of biopharmaceuticals. Her work encompasses a broad range of chromatographic techniques, ensuring comprehensive analytical solutions for the scientific and biopharmaceutical industries. Thanks to her extensive background in analytical chemistry and her dedication to advancing biopharmaceutical characterization, Sylvia’s a leading expert in her field. During the last few years, her work has focused on the Multi-Attribute Method (MAM) approach and the application of advanced LC-MS platforms to support the development of new therapeutic modalities such as oligonucleotide-based therapies.
Mauro De Pra, PhD
Product Marketing Manager
Thermo Fisher Scientific
Mauro De Pra, who has been with Thermo Fisher Scientific since 2010, has held roles spanning across product development, application development, technical support, and product marketing. His work focuses on HPLC and advanced separation technologies, supporting the development and commercialization of innovative LC solutions. Mauro has authored multiple peer-reviewed publications in the field of separation sciences and brings extensive experience translating analytical challenges into practical solutions for pharmaceutical and biopharmaceutical applications. Before joining Thermo Fisher Scientific, he worked as an Analytical Development Scientist in the Pharmaceutical industry. Mauro holds a Ph.D. in Chemistry from the University of Amsterdam.